Incretin mimetics have established a massive market in diabetes and obesity, but hold potential promise in other indications, as well. This paper describes how this evolving market might play out by addressing three key questions:
- What is the current state of the incretin mimetic market in diabetes and obesity, and how did we get here?
- What remaining unmet needs exist for incretin mimetics across diabetes and obesity, what strategies are being employed to address these
needs, and what factors determine who will win? - What other potential therapeutic areas could GLP-1s address, where is the white space, and how should companies evaluate where to play?
